This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Sandoz, RareGen had more than one way of entering heart drug market, United Therapeutics says in motion to dismiss

( June 25, 2019, 23:31 GMT | Official Statement) -- MLex Summary: Sandoz and RareGen's joint complaint against United Therapeutics Corporation and Smiths Medical ASD should be dismissed because they failed to plead they were entirely foreclosed from the market for pulmonary arterial hypertension, UTC said in a motion to dismiss. UTC argued the joint complaint only said they had been barred from one method of entering the market. Sandoz and RaregGen filed a complaint accusing UTC and Smiths of placing artificial restrictions on Smiths' injection cartridges to ensure they can only be used to administer a brand name treprostinil drug supplied by UTC.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections